HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a diabetes drug slow breast cancer growth?
Disease control Not yet recruitingThis phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a daily pill tame advanced breast cancer? new trial tests oral paclitaxel
Disease control Not yet recruitingThis Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to s…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug duo targets advanced breast cancer in phase 2 trial
Disease control Not yet recruitingThis study tests two experimental drugs, AK146D1 and AK112, given together to people with advanced breast cancer that has spread or come back. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 200 adults aged 18 to 75 with HER2-negativ…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy targets Hard-to-Treat breast cancer liver metastases
Disease control Not yet recruitingThis phase II trial tests whether combining multi-mode thermal therapy (heat treatment) with immunotherapy drugs can help people with HER2-negative breast cancer that has spread to the liver. The study will enroll 30 participants who have already tried at least one prior treatmen…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy offers hope for hard-to-treat breast cancer
Disease control Not yet recruitingThis study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Blood test may guide breast cancer therapy, reducing chemo need
Disease control Not yet recruitingThis phase 2 trial tests a personalized approach for early-stage, hormone receptor-positive breast cancer. Participants receive a combination of CDK4/6 inhibitors and endocrine therapy before surgery. A blood test (ctDNA) is used to monitor tumor DNA and may help decide if chemot…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Could electromagnetic fields help fight breast cancer?
Disease control Not yet recruitingThis study tests a device called TheraBionic P1 that sends low-level electromagnetic fields to the body. It is for people with advanced hormone-positive, HER2-negative breast cancer who have already tried standard treatments. The goal is to see if the device can help control the …
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can better Doctor-Patient talks improve breast cancer care?
Symptom relief Not yet recruitingThis study tests whether training doctors in shared decision-making and giving patients educational materials improves treatment conversations for HER2-negative metastatic breast cancer. 120 patients starting first-line therapy will be randomly assigned to receive the program or …
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Federico II University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC